Posted by Michael Wonder on 07 Feb 2025
FDA grants priority review to Insmed's brensocatib for treatment of bronchiectasis
6 February 2025 - Brensocatib would be the first and only available treatment for bronchiectasis and first DPP1 inhibitor, if approved.
Insmed today announced that the US FDA has accepted the Company's new drug application for brensocatib for patients with non-cystic fibrosis bronchiectasis.
